期刊文献+

伏立康唑致精神、视觉障碍和肝功能异常1例 被引量:18

One case of mental and visual impairment and abnormal liver function induced by voriconazole
下载PDF
导出
摘要 1例56岁男性患者,20余年前体检发现HBsAg阳性,肝功能不详,曾口服拉米夫定抗病毒治疗2年,后自行停药。之后间断服用中成药、中草药等护肝治疗,因腹胀、乏力,为进一步诊治来我院就诊,诊断乙型肝炎肝硬化失代偿期合并腹水、腹膜炎,因肺部真菌感染应用伏立康唑抗真菌治疗,用药12 d后出现肝酶波段性升高,同时出现视弱、畏光、上肢震颤及惊厥。进行血药浓度监测,显示伏立康唑血药浓度12.64 mg·L^(-1),停药3 d后,不良反应消失,伏立康唑血药浓度降至4.96 mg·L^(-1)。 One56-year-old male patient was diagnosed as HBsAg positive in a physical examination20years ago and the liver function was unknown.The patient took lamivudine for antiviral treatment for2years.The patient received intermittent treatment with Chinese patent medicine and herbal medicine in order to protect the liver.The patient was admitted with a complaintof abdominal distension and fatigue,and diagnosed as decompensated hepatitis B cirrhosis with ascites and peritonitis.The patient took voriconazole for pulmonary fungal infection,after12days of treatment,the liver enzyme bands increased,at the same time photophobia,tremor and convulsion occured.Monitoring of blood concentration showed voriconazole concentration of12.64mg·L-1,3days after drug withdrawal,the adverse reactions disappeared,blood concentration reduced to4.96mg·L-1.
作者 冯飞飞 张晓云 任秋霞 谢英 朱红 赵美 赵庆国 FENG Fei-fei;ZHANG Xiao-yun;REN Qiu-xia;XIE Ying;ZHU Hong;ZHAO Mei;ZHAO Qing-guo(Department of Pharmacy, 302 Hospital of PLA, Beijing 100039, China;Central Theater Air Force Command Headquarters, Beijing 100061, China)
出处 《中国药物应用与监测》 CAS 2017年第2期128-129,共2页 Chinese Journal of Drug Application and Monitoring
基金 国家临床重点专科军队建设项目(413FJH)
关键词 伏立康唑 血药浓度监测 药品不良反应 Voriconazole Blood concentration monitoring Adverse drug reaction
  • 相关文献

参考文献3

二级参考文献50

  • 1王英,王建钊,顾军,张丽娟,李秀凯.伏立康唑、氟康唑和两性霉素B体内抗克柔念珠菌活性的比较研究[J].中国皮肤性病学杂志,2006,20(8):455-457. 被引量:3
  • 2刘玮,杨新良,王雪松,王俊,蔡璐,郁祁.国产伏立康唑治疗耐氟康唑念珠菌深部感染疗效观察[J].临床药物治疗杂志,2007,5(1):32-34. 被引量:7
  • 3白桦,张千.老年脑卒中患者医院获得性肺炎73例临床分析[J].广西医学,2007,29(4):559-561. 被引量:5
  • 4GilbertDN,MoelleringRC,EIiopoulosGM,eta1.桑福德抗微生物治疗指南[M].汪伟业,宋关鸿,万谟彬,译.第39版.北京:中国协和医科大学出版社,2010:40.
  • 5Madhavan P, Jamal F, Chong PP, et al. In vitro activity of ftuconazole and voriconazole against clinical isolates of Candida spp. by E-test method[J]. Trop Biomed, 2010, 27(2): 200-207.
  • 6Quindds G, Sanchez-Vargas LO, Villar-Vidal M, et al. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre[J]. Int J Antimicrob Agents, 2008, 31(3) : 266-271.
  • 7Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring[J]. Antimicrob Agents Chemother, 2006, 50(4):1570-1572.
  • 8Ueda K, Nannya Y, Kumano K, et al. Monitroring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders[J]. Int J Hematol, 2009, 89(5): 592-599.
  • 9Lutsar 1, Roffey S, Troke E Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immuno- compromised patients[J]. Clin Infect Dis, 2003, 37(5): 728-732.
  • 10Quintard H, Papy E, Massias L, et al. The pharmacokinetic profile of voriconazole during continuous high-volume venovenous hemofiltration in a critically ill patient[J]. Ther Drug Monit, 2008, 30(1): 117-119.

共引文献45

同被引文献121

引证文献18

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部